Ipca Laboratories Limited

Ipca is a consumer-led global pharmaceutical company, creating healthy doses of life since 1949.

For more than 60 years, Ipca has been a crucial healthcare partner in over 120 countries across the 6 continents. Ipca is a fully-integrated pharmaceutical company that manufactures over 350 formulations and 80 APIs for various therapeutic segments.

Ipca has a diverse product portfolio catering to major therapeutic segments in virtually every dosage form – Oral solids, powder for suspension and small volume injections (dry & liquid).

Ipca manufactures over 350 formulations with 4 of its branded formulations being ranked amongst the top 300 brands of Indian Pharma Market as per IQVIA May 2020. Ipca is also leaders in Pain, Rheumatology, Antimalarials and Haircare therapies with a steadily growing portfolio.

Having established the essence and resolve to compete in the growing generic arena we have fortified our capabilities in terms of infrastructure with 4 dedicated manufacturing facilities catering to regulated markets, having accreditation from Health Canada, Government of Oberfranken-Germany, Halmed-Croatia, MHRA-UK, TGA-Australia, SAHPRA-South Africa, and WHO-Geneva. Our state of the art facilities are designed with an eye on addressing the economies of scale offering a competitive edge.

Ipca is one of the world’s largest manufacturers and suppliers of over a dozen APIs. Ipca’s manufacturing leadership extends across Atenolol (anti-hypertensive), Chloroquine Phosphate (anti-malarial), Chlorthalidone (diuretic), Furosemide (diuretic), Hydroxychloroquine Sulphate (DMARD), Losartan (anti-hypertensive), Metoprolol Succinate (anti-hypertensive), Metoprolol Tartrate (anti-hypertensive), Pyrantel Salts (anthelmintic), and Propranolol (anti-hypertensive) – besides being one of the largest suppliers of these APIs worldwide.